8-K: Aspira Womens Health Loses $6.5 Million ARPA-H Funding for Endometriosis Test Development

Aspira Womens Health Inc. announced the termination of its $10 million contract with ARPA-H for the development of its ENDOinform endometriosis diagnostic test, having received $3.5 million prior to termination.

Summary

• Aspira Womens Health Inc. (Aspira) announced that its contract with the Advanced Research Projects Agency for Health (ARPA-H) for the Sprint for Womens Health program has been terminated.
• The contract, originally announced on October 24, 2024, was a $10 million award intended to support the development of Aspira's ENDOinform test, a non-invasive blood-based diagnostic for endometriosis.
• Aspira had received two milestone payments totaling $3.5 million ($2 million on November 29, 2024, and $1.5 million on March 28, 2025) from the ARPA-H program before the termination.
• ARPA-H and its managing contractor, VentureWell, notified Aspira on June 9, 2025, that the contract was terminated because Aspira had not met the specifications of Milestone 3.
• Aspira's CEO, Mike Buhle, stated that the company is highly confident it fully achieved all Milestone 3 requirements and is well underway with Milestone 4, expressing confidence in their quality of work and technical understanding.
• Despite the termination, Aspira plans to continue the development of the ENDOinform program, which remains targeted for 2026 completion goals, with support from shareholders, research partners, and its team.
• The company believes that compliance with the ARPA-H program involved significant time investment, and its termination may allow for a material acceleration in achieving its development goals.

Sentiment

Score: 3

Explanation: The sentiment is predominantly negative due to the termination of a significant $10 million government contract, resulting in a loss of $6.5 million in funding. While management expresses confidence in their progress and commitment to continue development, the financial setback and the dispute over milestone achievement are substantial negatives. The potential for 'acceleration' is a forward-looking statement and does not offset the immediate financial loss.

Positives

• Aspira's management expresses high confidence that their team fully achieved all Milestone 3 specifications and is well underway with Milestone 4, indicating strong internal progress.
• The company remains committed to continuing the development of the ENDOinform program, targeting 2026 completion goals, despite the loss of ARPA-H funding.
• Management suggests that the termination of the ARPA-H program, which involved significant time investment for their R&D team, may actually lead to a material acceleration in achieving their development goals for ENDOinform.

Negatives

• The contract with ARPA-H, originally valued at $10 million, has been terminated, resulting in a loss of $6.5 million in anticipated funding for the ENDOinform development program.
• ARPA-H and its managing contractor determined that Aspira had not met the specifications of Milestone 3, leading to the termination.
• The termination introduces uncertainty regarding future funding for the ENDOinform program, which will now rely on shareholder support and other partners.

Risks

• Forward-looking statements regarding the timing and completion of products in the development pipeline, such as ENDOinform, involve inherent risks and uncertainties.
• Actual results could differ materially from expectations due to known and unknown risks, including those identified as Risk Factors in the company's SEC filings (Form 10-K and 10-Q).
• The loss of $6.5 million in ARPA-H funding may impact the pace or scope of the ENDOinform development if alternative funding sources are not secured or if the company's internal resources are insufficient.
• Despite management's confidence, there is a risk that the company's assessment of having met Milestone 3 specifications differs from ARPA-H's, potentially leading to further disputes or challenges.

Future Outlook

Aspira plans to continue the development of its ENDOinform program, a non-invasive diagnostic test for endometriosis, with a target completion goal of 2026. The company believes that the termination of the ARPA-H contract, by freeing up R&D team time previously spent on compliance, may materially accelerate the pace of achieving these development goals.

Management Comments

• "While we are certainly disappointed in ARPA-H’s termination notice, we are highly confident that our team fully achieved all specifications requirements in the Milestone 3 scope of work provisions."
• "We achieved these requirements in early May and are well underway in achieving Milestone 4 targeted specifications."
• "We are confident in our quality of work, and even more so in our understanding of the technical requirements to complete the ENDOinform program."
• "Our R&D team has been excited about the progress we have made, as well as the early indications of our potential success with the ENDOinform program overall."
• "We plan to continue development of this critical women’s health program with the help and support of our shareholders, our research & collaboration partners, and the ongoing dedication of our highly talented and missional teammates."
• "ENDOinform promises a dramatic improvement in health outcomes and quality of life for millions of women suffering from endometriosis, both in the U.S. and abroad. The program remains targeted for 2026 completion goals. We look forward to continuing our development work to completion."
• "In fact, compliance with the ARPA-H program involved significant time investment for our R&D team, and this may well offer us a material acceleration in the pace of achieving our goals."

Industry Context

This announcement highlights the ongoing efforts within the women's health industry to address critical unmet needs, particularly in the diagnosis of debilitating conditions like endometriosis. Aspira's focus on non-invasive, AI-powered bio-analytics tests aligns with broader trends towards less invasive and more precise diagnostic tools. The termination of a significant government contract (ARPA-H) underscores the high-stakes and rigorous nature of public-private partnerships in medical innovation, even for promising technologies aimed at improving health outcomes.

Stakeholder Impact

• Shareholders: Will bear the financial impact of the lost funding and may be called upon for future support to continue the ENDOinform program.
• Patients: The continued development of ENDOinform, if successful, promises improved health outcomes and quality of life for millions suffering from endometriosis.
• R&D Team: Experienced significant time investment in ARPA-H compliance, and the termination may allow for a re-prioritization and potential acceleration of development efforts.

Next Steps

• Aspira plans to continue the development of its ENDOinform program for endometriosis diagnosis.
• The company will seek support from shareholders, research and collaboration partners, and its internal team to complete the program.
• Aspira aims to achieve the ENDOinform program's completion goals, which remain targeted for 2026.

Key Dates

Keywords

Aspira Womens Health, AWHL, ARPA-H, Endometriosis, ENDOinform, Womens Health, Diagnostics, AI-powered, Biomarkers, Contract Termination, SEC Filing, Medical Technology, Ovarian Cancer